Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

LTBP3 promotes early metastatic events during cancer cell dissemination.

Deryugina EI, Zajac E, Zilberberg L, Muramatsu T, Joshi G, Dabovic B, Rifkin D, Quigley JP.

Oncogene. 2018 Apr;37(14):1815-1829. doi: 10.1038/s41388-017-0075-1. Epub 2018 Jan 19.

2.

Ogilvie's syndrome treated with an emergency laparotomy, right hemicolectomy and end ileostomy.

Robinson AJ, Quigley JP, Banks A, Farmer M.

BMJ Case Rep. 2017 Oct 9;2017. pii: bcr-2017-220916. doi: 10.1136/bcr-2017-220916.

3.

Patient compliance with venous thromboembolism prophylaxis (VTE).

Blackwell JR, Raval P, Quigley JP, Patel A, McBride D.

J Clin Orthop Trauma. 2017 Apr-Jun;8(2):201-205. doi: 10.1016/j.jcot.2017.03.009. Epub 2017 Apr 14.

4.

Activated tumor cell integrin αvβ3 cooperates with platelets to promote extravasation and metastasis from the blood stream.

Weber MR, Zuka M, Lorger M, Tschan M, Torbett BE, Zijlstra A, Quigley JP, Staflin K, Eliceiri BP, Krueger JS, Marchese P, Ruggeri ZM, Felding BH.

Thromb Res. 2016 Apr;140 Suppl 1:S27-36. doi: 10.1016/S0049-3848(16)30095-0.

5.

EGFR regulates the development and microarchitecture of intratumoral angiogenic vasculature capable of sustaining cancer cell intravasation.

Minder P, Zajac E, Quigley JP, Deryugina EI.

Neoplasia. 2015 Aug;17(8):634-49. doi: 10.1016/j.neo.2015.08.002.

6.

Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature.

Deryugina EI, Quigley JP.

Matrix Biol. 2015 May-Jul;44-46:94-112. doi: 10.1016/j.matbio.2015.04.004. Epub 2015 Apr 22. Review.

7.

Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment.

Deryugina EI, Zajac E, Juncker-Jensen A, Kupriyanova TA, Welter L, Quigley JP.

Neoplasia. 2014 Oct 23;16(10):771-88. doi: 10.1016/j.neo.2014.08.013. eCollection 2014 Oct.

8.

Circular trimers of gelatinase B/matrix metalloproteinase-9 constitute a distinct population of functional enzyme molecules differentially regulated by tissue inhibitor of metalloproteinases-1.

Vandooren J, Born B, Solomonov I, Zajac E, Saldova R, Senske M, Ugarte-Berzal E, Martens E, Van den Steen PE, Van Damme J, Garcia-Pardo A, Froeyen M, Deryugina EI, Quigley JP, Moestrup SK, Rudd PM, Sagi I, Opdenakker G.

Biochem J. 2015 Jan 15;465(2):259-70. doi: 10.1042/BJ20140418.

9.

Angiogenic capacity of M1- and M2-polarized macrophages is determined by the levels of TIMP-1 complexed with their secreted proMMP-9.

Zajac E, Schweighofer B, Kupriyanova TA, Juncker-Jensen A, Minder P, Quigley JP, Deryugina EI.

Blood. 2013 Dec 12;122(25):4054-67. doi: 10.1182/blood-2013-05-501494. Epub 2013 Oct 30.

10.

Tumor MMP-1 activates endothelial PAR1 to facilitate vascular intravasation and metastatic dissemination.

Juncker-Jensen A, Deryugina EI, Rimann I, Zajac E, Kupriyanova TA, Engelholm LH, Quigley JP.

Cancer Res. 2013 Jul 15;73(14):4196-211. doi: 10.1158/0008-5472.CAN-12-4495. Epub 2013 May 16.

11.

Twist1 induces CCL2 and recruits macrophages to promote angiogenesis.

Low-Marchelli JM, Ardi VC, Vizcarra EA, van Rooijen N, Quigley JP, Yang J.

Cancer Res. 2013 Jan 15;73(2):662-71. doi: 10.1158/0008-5472.CAN-12-0653.

12.

In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling.

Casar B, Rimann I, Kato H, Shattil SJ, Quigley JP, Deryugina EI.

Oncogene. 2014 Jan 9;33(2):255-68. doi: 10.1038/onc.2012.547. Epub 2012 Dec 3.

13.

Cell surface remodeling by plasmin: a new function for an old enzyme.

Deryugina EI, Quigley JP.

J Biomed Biotechnol. 2012;2012:564259. doi: 10.1155/2012/564259. Epub 2012 Oct 14. Review.

14.

The primacy of β1 integrin activation in the metastatic cascade.

Kato H, Liao Z, Mitsios JV, Wang HY, Deryugina EI, Varner JA, Quigley JP, Shattil SJ.

PLoS One. 2012;7(10):e46576. doi: 10.1371/journal.pone.0046576. Epub 2012 Oct 3.

15.

Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.

Botkjaer KA, Deryugina EI, Dupont DM, Gårdsvoll H, Bekes EM, Thuesen CK, Chen Z, Ploug M, Quigley JP, Andreasen PA.

Mol Cancer Res. 2012 Dec;10(12):1532-43. doi: 10.1158/1541-7786.MCR-12-0349. Epub 2012 Oct 4. Erratum in: Mol Cancer Res. 2013 Aug;11(8):964. Chen, Zhou [corrected to Chen, Zhuo].

16.

Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells.

Casar B, He Y, Iconomou M, Hooper JD, Quigley JP, Deryugina EI.

Oncogene. 2012 Aug 30;31(35):3924-38. doi: 10.1038/onc.2011.555. Epub 2011 Dec 19.

17.

Combating angiogenesis early: potential of targeting tumor-recruited neutrophils in cancer therapy.

Quigley JP, Deryugina EI.

Future Oncol. 2012 Jan;8(1):5-8. doi: 10.2217/fon.11.133. No abstract available.

18.

Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.

Bekes EM, Deryugina EI, Kupriyanova TA, Zajac E, Botkjaer KA, Andreasen PA, Quigley JP.

Neoplasia. 2011 Sep;13(9):806-21.

19.

Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation.

Bekes EM, Schweighofer B, Kupriyanova TA, Zajac E, Ardi VC, Quigley JP, Deryugina EI.

Am J Pathol. 2011 Sep;179(3):1455-70. doi: 10.1016/j.ajpath.2011.05.031. Epub 2011 Jul 8.

20.

Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.

Botkjaer KA, Fogh S, Bekes EC, Chen Z, Blouse GE, Jensen JM, Mortensen KK, Huang M, Deryugina E, Quigley JP, Declerck PJ, Andreasen PA.

Biochem J. 2011 Aug 15;438(1):39-51. doi: 10.1042/BJ20110129.

21.

Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta.

He Y, Wortmann A, Burke LJ, Reid JC, Adams MN, Abdul-Jabbar I, Quigley JP, Leduc R, Kirchhofer D, Hooper JD.

J Biol Chem. 2010 Aug 20;285(34):26162-73. doi: 10.1074/jbc.M109.096453. Epub 2010 Jun 15.

22.

Inhibition of tumor metastasis: functional immune modulation of the CUB domain containing protein 1.

Fukuchi K, Steiniger SC, Deryugina E, Liu Y, Lowery CA, Gloeckner C, Zhou B, Kaufmann GF, Quigley JP, Janda KD.

Mol Pharm. 2010 Feb 1;7(1):245-53. doi: 10.1021/mp900236t.

23.

Leptin enhances the potency of circulating angiogenic cells via src kinase and integrin (alpha)vbeta5: implications for angiogenesis in human obesity.

Heida NM, Leifheit-Nestler M, Schroeter MR, Müller JP, Cheng IF, Henkel S, Limbourg A, Limbourg FP, Alves F, Quigley JP, Ruggeri ZM, Hasenfuss G, Konstantinides S, Schäfer K.

Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):200-6. doi: 10.1161/ATVBAHA.109.192807. Epub 2009 Nov 12.

24.

Evaluation of metastatic and angiogenic potentials of human colon carcinoma cells in chick embryo model systems.

Subauste MC, Kupriyanova TA, Conn EM, Ardi VC, Quigley JP, Deryugina EI.

Clin Exp Metastasis. 2009;26(8):1033-47. doi: 10.1007/s10585-009-9293-4. Epub 2009 Oct 20.

25.

Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions.

Deryugina EI, Quigley JP.

Biochim Biophys Acta. 2010 Jan;1803(1):103-20. doi: 10.1016/j.bbamcr.2009.09.017. Epub 2009 Oct 2. Review.

26.

Comparative analysis of metastasis variants derived from human prostate carcinoma cells: roles in intravasation of VEGF-mediated angiogenesis and uPA-mediated invasion.

Conn EM, Botkjaer KA, Kupriyanova TA, Andreasen PA, Deryugina EI, Quigley JP.

Am J Pathol. 2009 Oct;175(4):1638-52. doi: 10.2353/ajpath.2009.090384. Epub 2009 Sep 3.

27.

Functional role of cell surface CUB domain-containing protein 1 in tumor cell dissemination.

Deryugina EI, Conn EM, Wortmann A, Partridge JJ, Kupriyanova TA, Ardi VC, Hooper JD, Quigley JP.

Mol Cancer Res. 2009 Aug;7(8):1197-211. doi: 10.1158/1541-7786.MCR-09-0100. Epub 2009 Aug 11.

28.

Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway.

Ardi VC, Van den Steen PE, Opdenakker G, Schweighofer B, Deryugina EI, Quigley JP.

J Biol Chem. 2009 Sep 18;284(38):25854-66. doi: 10.1074/jbc.M109.033472. Epub 2009 Jul 16.

29.

The cell surface glycoprotein CDCP1 in cancer--insights, opportunities, and challenges.

Wortmann A, He Y, Deryugina EI, Quigley JP, Hooper JD.

IUBMB Life. 2009 Jul;61(7):723-30. doi: 10.1002/iub.198. Review.

30.

A novel mode of intervention with serine protease activity: targeting zymogen activation.

Blouse GE, Bøtkjaer KA, Deryugina E, Byszuk AA, Jensen JM, Mortensen KK, Quigley JP, Andreasen PA.

J Biol Chem. 2009 Feb 13;284(7):4647-57. doi: 10.1074/jbc.M804922200. Epub 2008 Dec 1.

31.
32.

Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis.

Deryugina EI, Quigley JP.

Histochem Cell Biol. 2008 Dec;130(6):1119-30. doi: 10.1007/s00418-008-0536-2. Epub 2008 Nov 13. Review.

33.

Cell surface proteomics identifies molecules functionally linked to tumor cell intravasation.

Conn EM, Madsen MA, Cravatt BF, Ruf W, Deryugina EI, Quigley JP.

J Biol Chem. 2008 Sep 26;283(39):26518-27. doi: 10.1074/jbc.M803337200. Epub 2008 Jul 24.

34.

The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151.

Zijlstra A, Lewis J, Degryse B, Stuhlmann H, Quigley JP.

Cancer Cell. 2008 Mar;13(3):221-34. doi: 10.1016/j.ccr.2008.01.031.

35.

Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis.

Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP.

Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20262-7. Epub 2007 Dec 11.

36.

Contribution of leptin receptor N-linked glycans to leptin binding.

Kamikubo Y, Dellas C, Loskutoff DJ, Quigley JP, Ruggeri ZM.

Biochem J. 2008 Mar 15;410(3):595-604.

PMID:
17983356
37.

The type II transmembrane serine protease matriptase-2--identification, structural features, enzymology, expression pattern and potential roles.

Ramsay AJ, Reid JC, Velasco G, Quigley JP, Hooper JD.

Front Biosci. 2008 Jan 1;13:569-79. Review.

PMID:
17981570
38.

Functional analysis of matrix metalloproteinases and tissue inhibitors of metalloproteinases differentially expressed by variants of human HT-1080 fibrosarcoma exhibiting high and low levels of intravasation and metastasis.

Partridge JJ, Madsen MA, Ardi VC, Papagiannakopoulos T, Kupriyanova TA, Quigley JP, Deryugina EI.

J Biol Chem. 2007 Dec 7;282(49):35964-77. Epub 2007 Sep 25.

39.
40.

Matrix metalloproteinases and tumor metastasis.

Deryugina EI, Quigley JP.

Cancer Metastasis Rev. 2006 Mar;25(1):9-34. Review.

PMID:
16680569
41.

Activity-based protein profiling implicates urokinase activation as a key step in human fibrosarcoma intravasation.

Madsen MA, Deryugina EI, Niessen S, Cravatt BF, Quigley JP.

J Biol Chem. 2006 Jun 9;281(23):15997-6005. Epub 2006 Apr 12.

42.

Viral nanoparticles as tools for intravital vascular imaging.

Lewis JD, Destito G, Zijlstra A, Gonzalez MJ, Quigley JP, Manchester M, Stuhlmann H.

Nat Med. 2006 Mar;12(3):354-60. Epub 2006 Feb 26.

43.

Unexpected effect of matrix metalloproteinase down-regulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination.

Deryugina EI, Zijlstra A, Partridge JJ, Kupriyanova TA, Madsen MA, Papagiannakopoulos T, Quigley JP.

Cancer Res. 2005 Dec 1;65(23):10959-69.

44.

Proangiogenic role of neutrophil-like inflammatory heterophils during neovascularization induced by growth factors and human tumor cells.

Zijlstra A, Seandel M, Kupriyanova TA, Partridge JJ, Madsen MA, Hahn-Dantona EA, Quigley JP, Deryugina EI.

Blood. 2006 Jan 1;107(1):317-27. Epub 2005 Sep 20.

45.

Genetic reprogramming of tumor cells by zinc finger transcription factors.

Blancafort P, Chen EI, Gonzalez B, Bergquist S, Zijlstra A, Guthy D, Brachat A, Brakenhoff RH, Quigley JP, Erdmann D, Barbas CF 3rd.

Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11716-21. Epub 2005 Aug 4.

46.

Collagenolysis-dependent angiogenesis mediated by matrix metalloproteinase-13 (collagenase-3).

Zijlstra A, Aimes RT, Zhu D, Regazzoni K, Kupriyanova T, Seandel M, Deryugina EI, Quigley JP.

J Biol Chem. 2004 Jun 25;279(26):27633-45. Epub 2004 Apr 5.

47.

Increase of anti-metastatic efficacy by selectivity- but not affinity-optimization of synthetic serine protease inhibitors.

Banke IJ, Arlt MJ, Pennington C, Kopitz C, Steinmetzer T, Schweinitz A, Gansbacher B, Quigley JP, Edwards DR, Stürzebecher J, Krüger A.

Biol Chem. 2003 Oct-Nov;384(10-11):1515-25.

PMID:
14669995
48.

Matrix metalloproteases and tumor dissemination.

Quigley JP.

Pathophysiol Haemost Thromb. 2003;33 Suppl 1:62-3. No abstract available.

49.

Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer.

Netzel-Arnett S, Hooper JD, Szabo R, Madison EL, Quigley JP, Bugge TH, Antalis TM.

Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):237-58. Review.

PMID:
12784999
50.

Mouse matriptase-2: identification, characterization and comparative mRNA expression analysis with mouse hepsin in adult and embryonic tissues.

Hooper JD, Campagnolo L, Goodarzi G, Truong TN, Stuhlmann H, Quigley JP.

Biochem J. 2003 Aug 1;373(Pt 3):689-702.

Supplemental Content

Loading ...
Support Center